Author Archives: admin


Interventional Pain Management Specialist Dr. Kaliq Chang with Atlantic Spine Center offers tips on emerging treatment using your body’s own cells -…

Dr. Kaliq Chang

WEST ORANGE, N.J. (PRWEB) October 08, 2020

Among the wide array of treatments available for chronic back pain, one is emerging thats distinct because it uses your bodys own cells to help you heal. Its called PRP, or platelet-rich plasma.

With two decades of research largely supporting PRPs benefits for conditions such as shoulder and knee pain, growing evidence suggests the minimally invasive treatment can also safely improve highly common lower back pain, says Kaliq Chang, MD, of Atlantic Spine Center.

PRP Platelet-rich plasma treatment involves taking a small sample of your blood and placing it in a machine called a centrifuge, which separates blood components. The plasma, or liquid, part of your blood is then placed in a syringe and injected into the painful area of your back while a special x-ray helps pinpoint where its needed most, Dr. Chang explains.

Within weeks, PRP treatment often results in significantly less back pain and a greater ability to perform everyday activities, he says.

More and more patients with lingering low back pain are inquiring about PRP to help rid them of the problem, adds Dr. Chang, an interventional pain management specialist. While additional data is still needed, its great to be able to tell them that PRP is becoming yet another sturdy tool in our arsenal of treatments to help beat back pain.

How does PRP work? Blood contains many substances that help promote the bodys healing process, and PRP treatment was developed on this premise, Dr. Chang says. As the so-called building blocks of blood, platelets which also help form scabs on abrasions, for example contain chemicals known as growth factors that support healing.

Also in platelets are proteins that trigger stem cells which can change into any type of cell to move toward an injured area. Growth factors and proteins work together to repair damaged tissue and make new, healthy tissue, Dr. Chang explains.

While our bodies normally carry out wound healing naturally, PRP injections concentrate those restorative cells at just the place we need them and in larger amounts, he says. In the lower back, this means damaged areas around the spine receive a much-needed boost to speed healing.

Back conditions PRP can help PRP isnt ideal for all types of low back pain, but your doctor after a thorough exam and workup may decide its a worthy option. What types of back problems can PRP treatment benefit? Pain caused by:

Degenerative disc disease, which are worn-down vertebral discs Muscle strains Damaged ligaments and tendons Muscle fibrosis

Two or three PRP treatments spaced over several months are optimal and seem to improve pain and function in the lower back more than a single treatment, Dr. Chang notes.

After an injection, you can expect to have some mild soreness near the injection site that lasts for a few days. Since PRP works by stimulating your natural healing response, it generally takes a few weeks before you start seeing the benefits. Because PRP is derived from your own blood, you cannot reject the cells a clear advantage, Dr. Chang says.

PRP treatments may also be combined with other approaches, such as physical therapy, to maximize the feel-good effects.

Mounting research suggests PRP is a safe, fast and powerful way to help facilitate healing in a hardworking area of our body the lower back, Dr. Chang says. Were happy to have a new and exciting way to help patients get back to their everyday activities with less pain and more joy.

Atlantic Spine Center is a nationally recognized leader for endoscopic spine surgery with several locations in NJ and NYC. http://www.atlanticspinecenter.com, http://www.atlanticspinecenter.nyc

Kaliq Chang, MD, is an interventional pain management specialist, double board-certified in interventional pain management and anesthesiology, at Atlantic Spine Center.

Share article on social media or email:

See original here:
Interventional Pain Management Specialist Dr. Kaliq Chang with Atlantic Spine Center offers tips on emerging treatment using your body's own cells -...

Was the antibody cocktail used to treat President Trump developed using human embryonic stem cells? – CBS News 8

Social media is buzzing with the claim President Trump, who is pro-life, used an antibody cocktail developed using human embryonic stem cells.

Editor's note Oct 8:Thursday News 8 received further clarification from Regeneron spokesperson, Alexander Bowie.

She says HEK293T (Human embryonic kidney 293 cells)were used to help evaluate the efficacy of antibodies that ultimately went into the antibody cocktail.

"These are not stem cells. We did not use human stem cells or human embryonic stem cells in the development of REGN-COV2.

Specifically, HEK293Ts were used to make pseudovirus that looks like the Spike protein of the SARS-CoV-2 virus, and this is used to test our antibodies ability to neutralize the virus. HEK293s are considered immortalized cells (again, not stem cells) and are a common and widespread tool in research labs. This cell line was originally derived by adenovirus transformation of human embryonic kidney cells in 1977. After this, it was further transformed at Stanford in the 80s with SV40 T-antigen (hence the T). HEK293T wasnt used in any other way, and fetal tissue was not used in this research."

The antibody cocktail used to treat President Donald Trump for COVID-19 is getting a lot of attention on social media.

Some users are claiming Regeneron - the company that developed the treatment - used human embryonic stem cells to create it, but is this true?

News 8 reached out to Regeneron for comment.

"This particular discovery program (regn-cov2) did not involve human stem cells or embryonic stem cells," wrote Regeneron spokesperson Alexandra Bowie in a statement.

So, where did that claim about human embryonic stem cells come from?

It appears to have developed from this statement Regeneron issued back in April 2020 regarding stem cell research:

"As is the case with many other science-focused biotechnology companies, Regeneron uses a wide variety of research tools and technologies to help discover and develop new therapeutics. stem cells are one such tool. the stem cells most commonly used at Regeneron are mouse embryonic stem cells and human blood stem cells. currently, there are limited research efforts employing human-induced pluripotent stem cell lines derived from adult human cells and human embryonic stem cells that are approved for research use by the national institutes of health and created solely through in vitro fertilization."

According to the American Association for the Advancement of Science, here's what the antibody cocktail used to treat the president is made of:

"One antibody comes from a human who had recovered from a SARS-COV-2 infection; a B cell that makes the antibody was harvested from the person's blood and the genes for the immune protein isolated and copied. The other antibody is from a mouse, which was engineered to have a human immune system, that had the spike protein injected into it."

Bowie also told News 8 the statement about stem cell research on its website reflects the company's general position on stem cell research, but does not mean human embryonic stem cells were used in creating the antibody cocktail used to treat the president.

Nevertheless, some said the company's position on using stem cells in general contradicts President Trump's pro-life stance and that of Supreme Court Nominee Amy Coney Barrett.

Editors Note:This story was originally posted as a VERIFY report.

Follow this link:
Was the antibody cocktail used to treat President Trump developed using human embryonic stem cells? - CBS News 8

AIVITA Biomedical’s Stem Cell Therapeutic in Vision Loss Published in Investigative Ophthalmology & Vision Science – BioSpace

IRVINE, Calif., Oct. 9, 2020 /PRNewswire/ --AIVITA Biomedical Inc., a private biotechnology company developing personalized vaccines for the treatment of cancer and COVID-19, announced today the publication of the peer-reviewed manuscript, "Retina organoid transplants develop photoreceptors and improve visual function in RCS rats with RPE dysfunction,"in the journal Investigative Ophthalmology & Visual Science. The study, led by researchers at AIVITA Biomedical and the Sue & Bill Gross Stem Cell Research Center of the University of California, Irvine, used 3D-retina organoids generated from human stem cells developed by AIVITA to provide insight into the potential use of transplanted retina organoids as a therapeutic option for blinding diseases.

In the study, transplanted retina organoid sheets were examined to determine if human stem cell-derived photoreceptors coulddevelop, survive and function in vivo without the support of healthy retina pigment epithelium (RPE). Visual function was examined through a variety of tests, including optokinetic testing (OKT), electroretinogram (ERG), and superior colliculus (SC) brain recording. These tests concluded that retina organoid transplantations demonstrated significant improvement in visual function compared to non-surgery and sham surgery controls, supporting the application of AIVITA's stem cell technologies in visual disease therapeutics.

"Leveraging our expertise in stem cell growth and differentiation, I'm excited to see the promise of our technology platform in potential therapeutics for vision loss," said Hans Keirstead, Ph.D., chief executive officer of AIVITA and a contributing author to the paper. "To our knowledge, this study is the first to show that it's possible for photoreceptors derived from stem cells to survive and function after transplantation when a host has a dysfunctional RPE."

This work is supported by funding from the California Institute for Regenerative Medicine (CIRM) and National Institutes of Health (NIH).

About AIVITA Biomedical AIVITA Biomedical is a privately held company engaged in the advancement of commercial and clinical-stage programs utilizing curative and regenerative medicines. Founded in 2016 by pioneers in the stem cell industry, AIVITA Biomedical utilizes its expertise in stem cell growth and directed, high-purity differentiation to enable safe, efficient and economical manufacturing systems which support its therapeutic pipeline and commercial line of skin care products. All proceeds from the sale of AIVITA's skin care products support the treatment of people with cancer.

View original content to download multimedia:http://www.prnewswire.com/news-releases/aivita-biomedicals-stem-cell-therapeutic-in-vision-loss-published-in-investigative-ophthalmology--vision-science-301149208.html

SOURCE AIVITA Biomedical, Inc.

Link:
AIVITA Biomedical's Stem Cell Therapeutic in Vision Loss Published in Investigative Ophthalmology & Vision Science - BioSpace

Boise State engineers given the opportunity to send stem cell research into space – Boise State University The Arbiter Online

Boise State engineers have been awarded $315,000 from the National Science Foundation (NSF) to launch stem cell research into space.

Alexander Regner, masters student in materials science engineering, has been working on stem cell research for nearly three years. Through Regners research, he has studied the health and maintenance of bone and bone marrow.

As you exercise and move, your bone marrow stimulates cells, which is a vital part of maintaining health, according to Regner.

Thats why exercise is so good for you. We know all of this contributes to health and maintenance, but we dont actually know what it looks like mechanically to these cells, Regner said.

Regner and his associates Gunes Uzer, assistant professor of mechanical and biomedical engineering, and Aykut Satici, assistant professor of mechanical and biomedical engineering, have created a model to mimic the bone marrow mechanical environment and analyze what kind of mechanical environment is causing the cells to react in certain ways.

Regner uses a computer simulation that matches a 3D printed physical sample. This allows Regner to understand what the mechanical environment looks like so they can correlate the mechanical environment to the cellular response.

Through this research, Regner asks the big question, is there a different mechanical environment generated due to changes in bone architecture?

Gunes and Satici looked at Regners research and wanted to bring it to a bigger audience. Their new goal was to determine how stem cell research can benefit Earth. According to Gunes, space travel tends to produce tissue types and cell behavior that is similar to aging. This aging happens over a matter of weeks in space, as opposed to a matter of years on Earth.

We take one of these bone cells and we age them for a year or two. But obviously, these bones have a shelf life, Gunes said. Maybe we can do that in space in three weeks and do the experiment in space. Maybe we can learn more about how the bone mechanical environment contributes to the aging process. Thats really the project, take Alexs work and send it to space.

Saticis contribution to this research is from a different perspective, robotics. According to Satici, there needs to be mechanical vibrations applied to particular cells. To accomplish this, there needs to be a robotic mechanism to perform that motion in a consistent matter.

Center for the Advancement of Science in Space (CASIS) holds a subcontract with the International Space Station along with the National Science Foundation (NSF). Each year, they ask the question, what type of research can we perform in space that can teach us something about Earth and improve advanced science on Earth?

Regner, Gunes and Satici argued that they cannot properly age experiments on Earth, and proposed that space could be a good platform for their research. They wrote a grant proposal for their research, what they have done in the past, what they plan to do and who is a part of the research team.

Regner, Gunes and Satici also work closely with the University of Texas, Rensselaer Polytechnic Institute and Space Tango to complete this research.

Through this extensive research, Regner, Satici and Gunes emphasize the importance of working hard to accomplish ones goals.

Just because its fun to do, doesnt mean you are going to learn it. You have to persevere and do the dirty work. Try to improve yourself with any resources you can get, Satici said.

Regner advocates for students to continuously work hard to help solve modern problems. There are a lot of job opportunities in the STEM field, and many jobs that may not require a STEM background at all, like politics.

A lot of our modern problems we are dealing with are multidisciplinary things. It requires the involvement of everyone. Space flight, for example, you need people to understand not only the mechanics but make sure were safe while were doing it, Regner said. [There are] a lot of problems we are facing in the middle age. If youre interested in helping solve them, there are so many different opportunities to get involved. If you want to go into politics, we need people to advocate for science in politics to make sure that we have adequate funding and focused goals for where we are going and what we are doing.

Gunes hopes students who want to get involved and achieve their goals will start with volunteer work.

Go to a lab youre interested in and say Hey, I want to do volunteering involving research. Before you know it you start getting your masters, your Ph.D., and then you become a scientist. If youre interested in [science] then stop thinking about it and do it, Gunes said.

Originally posted here:
Boise State engineers given the opportunity to send stem cell research into space - Boise State University The Arbiter Online

Stem Cell and Progenitor Cell-based Therapeutics Market Market Size, Share, Industry Report by Growt – PharmiWeb.com

Latest published market study on Global Stem Cell and Progenitor Cell-based Therapeutics Market with + data Tables, Pie Chart, high level qualitative chapters & Graphs is available now to provide complete assessment of the Market highlighting evolving trends, Measures taken up by players, current-to-future scenario analysis and growth factors validated with Viewpoints extracted via Industry experts and Consultants.Stem Cell and Progenitor Cell-based Therapeutics Market presents point by point serious investigation including the market Share, Size, Future extension. This investigation classifies the worldwide Stem Cell and Progenitor Cell-based Therapeutics breakdown information by makers, area, type and applications, likewise examines the market drivers, openings and difficulties. The study breaks market by revenue and volume (wherever applicable) and price history to estimates size and trend analysis and identifying gaps and opportunities. Some are the players that are in coverage of the study are VitroBioPharma, ViaCyte, Inc., Vericel., U.S. Stem Cell, Inc., Stemedica Cell Technologies, Inc, etc.

Data Bridge Market Research analyses the Stem Cell and Progenitor Cell-based Therapeutics Market to grow at a CAGR of 9.4% in the above-mentioned forecast period. Increasing focus on stem research is anticipated to create new opportunity for the stem cell & progenitor cell based therapeutics market.

Download Free Exclusive Sample (350 Pages PDF) Report: To Know the Impact of COVID-19 on this Industry@ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-stem-cell-and-progenitor-cell-based-therapeutics-market

Overview:

Increasing investment in the R&D and advancement in the stem cell based therapies is expected to enhance the market growth. Some of the other factors such as increasing public-private investments for advancement of stem cell therapies, development of infrastructure of stem cell banking & processing, and rising cases of Parkinson disease will affect the growth of this market.

Some of the factors such as improper guidelines associated with the product development and lack of skilled & trained professional for cell culture technology are hampering the growth of this market.

The Stem Cell and Progenitor Cell-based Therapeutics Market 2020 Document clearly explains what market definition, classifications, applications, engagements and market trends are for the Stem Cell and Progenitor Cell-based Therapeutics industry. The Global Stem Cell and Progenitor Cell-based Therapeutics Market Share analysis is provided for the international markets including development trends, competitive landscape analysis, and key regions development status. Development policies and plans are discussed as well as manufacturing processes and cost structures are also analyzed. This report also states import/export consumption, supply and demand Figures, cost, price, revenue and gross margins. For each manufacturer covered, this report analyzes their Stem Cell and Progenitor Cell-based Therapeutics manufacturing sites, capacity, production, ex-factory price, and revenue and market share in global market. This report studies the industry abilities for each geographical region based on the customer purchasing patterns, macroeconomic parameters, development rate, and market demand and supply states. What is more, it determines the impact of buyers, substitutes, new entrants, competitors, and suppliers on the market.

According to this report Global Stem Cell and Progenitor Cell-based Therapeutics Market will rise from Covid-19 crisis at moderate growth rate during 2020 to 2027. Stem Cell and Progenitor Cell-based Therapeutics Market includes comprehensive information derived from depth study on Stem Cell and Progenitor Cell-based Therapeutics Industry historical and forecast market data. Global Stem Cell and Progenitor Cell-based Therapeutics Market Size To Expand moderately as the new developments in Stem Cell and Progenitor Cell-based Therapeutics and Impact of COVID19 over the forecast period 2020 to 2027.

TO UNDERSTAND HOW COVID-19 IMPACT IS COVERED IN THIS REPORT, GET FREE COVID-19 SAMPLE @ https://www.databridgemarketresearch.com/covid-19-impact/global-stem-cell-and-progenitor-cell-based-therapeutics-market

Stem Cell and Progenitor Cell-based Therapeutics Market report provides depth analysis of the market impact and new opportunities created by the COVID19/CORONA Virus pandemic. Report covers Stem Cell and Progenitor Cell-based Therapeutics Market report is helpful for strategists, marketers and senior management, And Key Players in Stem Cell and Progenitor Cell-based Therapeutics Industry.

The Global Stem Cell and Progenitor Cell-based Therapeutics segments and Market Data Break Down are illuminated below:

By Disease Type (Parkinson Disease, Huntington Disease)

By Applications (Tissue Engineering, Stem Cells, Gene Therapy, Drug Discovery, Nanotechnology)

By End- Users (Pharmaceutical and Biotechnology Industries, Hospitals, Research Institutes, Biotechnology Companies, Others)

The report can help to understand the market and strategize for business expansion accordingly. In the strategy analysis, it gives insights from marketing channel and market positioning to potential growth strategies, providing in-depth analysis for new entrants or exists competitors in the Stem Cell and Progenitor Cell-based Therapeutics industry. This report also states import/export consumption, supply and demand Figures, cost, price, revenue and gross margins. For each manufacturer covered, this report analyzes their Stem Cell and Progenitor Cell-based Therapeutics manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.

List of TOP KEY PLAYERS in Stem Cell and Progenitor Cell-based Therapeutics Market Report are

Complete Report is Available (Including Full TOC, List of Tables & Figures, Graphs, and Chart) @ https://www.databridgemarketresearch.com/toc/?dbmr=global-stem-cell-and-progenitor-cell-based-therapeutics-market

Stem Cell and Progenitor Cell-based Therapeutics Industry 2020 Market Research Report provides exclusive vital statistics, data, information, trends and competitive landscape details in this niche sector. This reports provides current status for Stem Cell and Progenitor Cell-based Therapeutics market forecast till 2027. Likely, the report also focuses on global major manufacturers of Stem Cell and Progenitor Cell-based Therapeutics market providing information such as company profiles, product picture and specification, capacity, production, price, cost, revenue and contact information. Upstream raw materials and equipment and downstream demand analysis is also carried out.

Stem Cell and Progenitor Cell-based Therapeutics Report covers the manufacturers data, including: shipment, price, revenue, gross profit, interview record, business distribution etc., these data help the consumer know about the competitors better. This report also covers all the regions and countries of the world, which shows a regional development status, including market size, volume and value, as well as price data.

Global Stem Cell & Progenitor Cell-Based Therapeutics Market Scope and Market Size

Stem cell & progenitor cell-based therapeutics market is segmented of the basis of disease type, application and end- users. The growth amongst these segments will help you analyse meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

On the basis of disease type, the stem cell & progenitor cell-based therapeutics market is segmented into Parkinson disease and Huntington disease.

The application segment of the stem cell & progenitor cell-based therapeutics market is divided into tissue engineering, stem cells, gene therapy, drug discovery, and nanotechnology.

On the basis of end- users, the stem cell & progenitor cell-based therapeutics market is segmented into pharmaceutical and biotechnology industries, hospitals, research institutes, biotechnology companies and others.

For More Information or Query or Customization Before Buying, Visit @ https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-stem-cell-and-progenitor-cell-based-therapeutics-market

The report offers in-depth assessment of the growth and other aspects of the Stem Cell and Progenitor Cell-based Therapeutics market in important countries (regions), including:

What the Stem Cell and Progenitor Cell-based Therapeutics Market Report Contains:

Organization profiles of the main rivals alongside their strategic activities and market shares.

Assurance and examination of the macro and microeconomic variables that influence the Global Market, as per the regional analysis.

Market Overview for the Global Stem Cell and Progenitor Cell-based Therapeutics Market and the identification of the market elements, including development drivers, limitations, difficulties, and potential opportunities for the market.

Assurance of various elements in charge of changing the market scene, rising future chances and assurance of driving players, which can influence the market on a territorial scale.

Market analysis for the Global Stem Cell and Progenitor Cell-based Therapeutics Market, with an aggressive scene and geographic examination on a worldwide and territorial scale.

Order a Complete Research Report Enabled with COVID-19 Impact Coverage @ https://www.databridgemarketresearch.com/checkout/buy/singleuser/global-stem-cell-and-progenitor-cell-based-therapeutics-market

With tables and figures helping analyze worldwide Global Stem Cell and Progenitor Cell-based Therapeutics Market Forecast provides key statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the market.

The content of the study subjects includes a total of 15 CHAPTERS:

Chapter 1, to describe Stem Cell and Progenitor Cell-based Therapeutics product scope, market overview, market opportunities, market driving force and market risks.

Chapter 2, to profile the top manufacturers of Stem Cell and Progenitor Cell-based Therapeutics, with price, sales, revenue and global market share of Stem Cell and Progenitor Cell-based Therapeutics in 2018 and 2019.

Chapter 3, the Stem Cell and Progenitor Cell-based Therapeutics competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.

Chapter 4, the Stem Cell and Progenitor Cell-based Therapeutics breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2010 to 2020.

Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2010 to 2020.

Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2010 to 2020.

Chapter 12, Stem Cell and Progenitor Cell-based Therapeutics market forecast, by regions, type and application, with sales and revenue, from 2020 to 2027.

Chapter 13, 14 and 15, to describe Stem Cell and Progenitor Cell-based Therapeutics sales channel, distributors, customers, research findings and conclusion, appendix and data source.

Our Other Reports:-

Exosome Therapeutic Market Size, 2020-New Technological Change Helping Market, Application, Driver, Trends, Share and Forecasts by 2027

Healthcare Fraud Detection Market 2020-Global Technology, Development, Trends and Comprehensive Study: IBM, Optum, COTIVITI, McKesson, Wipro

Occupational Therapy Market 2020 Size, Share, Global Trends, Development Status, Opportunities, Competitive Landscape-WebPT, Premise Health, Net Health, CLINICIENT

Customization Service of the Report:

Data Bridge Market Research provides customization of reports as per your need. This report can be personalized to meet your requirements. Get in touch with our sales team (Corporatesales@databridgemarketresearch.com), who will guarantee you to get a report that suits your necessities.

AboutDataBridge Market Research:

An absolute way to forecast what future holds is to comprehend the trend today! Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate.

Contact Us:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Mail:Corporatesales@databridgemarketresearch.com

This content has been distributed via CDN Newswire press release distribution service. For press release enquires please mail us at contact@cdnnewswire.com.

Visit link:
Stem Cell and Progenitor Cell-based Therapeutics Market Market Size, Share, Industry Report by Growt - PharmiWeb.com

Thinking It Through: Only two of 12 statewide propositions should be approved – VVdailypress.com

By Richard Reeb | For the Victorville Daily Press

California is one of 24 states that authorize citizens to vote directly on legislation or constitutional amendments that are proposed either by the initiative of the voters, the legislature or referendum. After some lean ballots in recent years, we face a dozen measures come Nov. 3 on a variety of subjects, including health, civil rights, property taxes, voting rights, rent control, parole and bail, and consumer privacy.

An initiative statute that would authorize $5.5 billion in state bonds to fund stem cell research, which, with interest, would climb to $7.8 billion. Proponents claim that it dedicates $1.6 billion to brain research but say nothing about whether, as in its original form, it includes embryonic stem cells. Opponents suspect that is the case, condemning their destruction as unethical. I would add, as the less scrupulous Chinese Communist regime discovered, their cherished multifaceted character leads to wildly unpredictable results in human beings. Vote no.

An initiative constitutional amendment at least equally malicious as 14, as it aims to undercut the historic property tax reform effected by a famous initiative passed in 1978 that cut property taxes for all property owners, both residential and commercial. It does this by striking at what proponents believe is its alleged privileging of large commercial interests. But opponents not only believe the measure is unfair to small commercial properties, but predict that residential property owners are next if the measure passes. Vote no.

An especially obnoxious measure, a constitutional amendment proposed by the state legislature to overturn a 1996 amendment that put an end to racial discrimination under the guise of diversity in state hiring, contracting and college admissions. Despite covert efforts to ignore the ban of official violation of civil rights, the existing provision has generally succeeded. The claim of systemic racism is as bogus now as it was 24 years ago. Vote no.

This legislative constitutional amendment, is cut from the same cloth as 16 in that it gives preferential treatment, here by permitting convicts to obtain voting rights before they have completed their parole. Their debt to society is not paid on the day they leave their prison cell as they are still under the supervision of persons with the authority to revoke it. It does not matter, as proponents claim, that other states have taken this step. It still trivializes the voting privilege. Vote no.

This is equally ill-conceived, a legislative constitutional amendment extending voting rights to children months before their 18th birthday by allowing them to vote in the primary election if they qualify for the general election. Proponents thrill at adolescents participating in politics, ignoring the opponents valid counterargument that voting is a big responsibility that should be reserved for persons who actually have responsibilities. Vote no.

Yet another legislative constitutional amendment that attacks property inheritances by persons 55 and over as not deserving of the same tax-saving protections as other transfers. Proponents anticipate increased tax revenues but opponents see that as unfair to parents seeking to help their children. Vote no.

An initiative statute limiting access to parole for such crimes as misdemeanor shoplifting with actual jail time for the offenders. The current absurd policy permits perps to steal as much as $950 worth three times! before they face serious consequences. Besides ending this madness, the measure would expand DNA collection in cases of rape and murder. Critics fear excess confinement that would overload the prisons, which supporters discount. Vote yes.

An initiative statute that would allow hundreds of our local governments to impose rent control on residential properties over 15 years old. Proponents call this a useful tool against homelessness, but opponents say it undermines the existing state rent control and would drive up the cost of housing, thereby doing nothing to increase supply. Vote no.

An initiative statute aimed at freeing app-based transportation and delivery companies from Assembly Bill 5 that requires all contract job holders to be redefined as regular employees so that they are provided the benefits and costs, as well as possible unionization. Uber, Lyft and DoorDash qualified this measure and pay for advertisements. They tried to escape the confines of this law through court action but failed. The measure provides some employee benefits but opponents reject it root and branch. Vote yes.

An initiative statute that would require a medical professional on site for dialysis treatment. Proponents claim it combats poor hygiene but opponents argue that it would force many clinics to shut down. Would the passage of this measure lead to a similar requirement for blood work or x-rays? Vote no.

An initiative statute that aims to protect consumer privacy but it is so convoluted that critics fear it would have the opposite result. Proponents say it will check Big Techs data collection but opponents say that consumers ability to restrict them would take far too long.Vote no.

A referendum that would replace existing law that requires bail for persons accused of crime with a system based on public safety and flight risk, purportedly enabling poor defendants to avoid heavy financial burdens that well-to-do suspects easily bear. Proponents promise a fairer and safer process as well, but opponents are skeptical of its dependence on computer-generated profiling. Vote no.

Richard Reeb taught political science, philosophy and journalism at Barstow College from 1970 to 2003. He is the author of Taking Journalism Seriously: Objectivity as a Partisan Cause (University Press of America, 1999). He can be contacted at rhreeb@verizon.net.

View original post here:
Thinking It Through: Only two of 12 statewide propositions should be approved - VVdailypress.com

Oakland University researchers acquire flow cytometry cell sorter with NSF grant – 2020 – College of Arts and Sciences – News – OU Magazine – News at…

A grant from the National Science Foundation recently helped researchers at Oakland University acquire a flow cytometry cell sorter, a scientific instrument which will allow for hands-on collaborative research in the areas of amphibian biology, plant genomics, and stem cell biology.

A flow cytometry cell sorter is an instrument that is used to perform fluorescent activated cell sorting, which means it can separate or sort small particles, such as cells, chemical compounds, beads, and proteins that are suspended in a stream of fluid, said Dr. Luis Villa-Diaz, an assistant professor in the Biological Sciences and Bioengineering departments at OU.

It does this based on fluorescent signals coming from the particle after it has been stimulated by lasers in the instrument, Villa-Diaz said. If the laser signal makes the particle glow, then a computer will detect that signal and quantify it, and also will direct that particle to a particular container to be collected. Then we can recover the desired particles after theyre sorted and use them for other experiments or purposes.

The flow cytometry cell sorter was obtained using a Major Research Instrumentation (MRI) grant provided by the National Science Foundation. Under the terms of the grant, the NSF covered 70 percent of the cost approximately $544,073 while a collaboration between the Office of the Provost, the College of Arts and Sciences, the Department of Biological Sciences, the Department of Chemistry, the Eye Research Institute, and the Center for Biomedical Research provided the remaining 30 percent ($233,174).

Villa-Diaz will serve as principal investigator on the grant, while Dr. Shailesh Lal, a professor of Biological Sciences and chair of the Bioengineering Department; Dr. Thomas Raffel, an associate professor of Biological Sciences; and Dr. Gerard Madlambayan, an associate professor of Biological Sciences, will serve as co-principal investigators.

I will be using the flow cell sorter to separate different populations of stem cells based on the expression of proteins at their cell membrane, Villa-Diaz said. After sorting and enrichment of the desired cells, we will be able to use and compare the different cell populations using other experimental conditions.

The flow cytometry cell sorter can also be used for a variety of other projects, including the determination of basic biological functions and signaling directed by cell surface proteins in stem cells, the role of endothelial cells on anti-apoptotic pathways, the regulation of pre-mRNA processing in plants, the effects of temperature in amphibian immunology, the development of tubular organs, and basic understanding of DNA repair mechanisms.

The instrument will be available for use by all investigators at OU and investigators from neighboring educational institutions, as well as by users coming from other industries, although there will be a fee involved, Villa-Diaz said. The instrument will also be used for educational purposes in multiple classes, including biology, chemistry and bioengineering.

For more information regarding the use of the instrument, contact Kathie Lesich at lesich@oakland.edu or Suraj Timilsina at surajtimilsina@oakland.edu.

Excerpt from:
Oakland University researchers acquire flow cytometry cell sorter with NSF grant - 2020 - College of Arts and Sciences - News - OU Magazine - News at...

California propositions: What you should know before voting – The Mercury News

The vote for president may be the item on the ballot that is drawing the most attention, but California voters are faced with another slate of propositions.

Of the 12 measures on this years ballot, some may feel very familiar. Others are all new.

Its a lot to consider. And now that ballots have been mailed to Californians, its a good time to find out what each proposition is about.

Heres a primer:

Vote yes for this and state taxpayers will be on the hook for $5.5 billion in bonds aimed at reviving the California Institute for Regenerative Medicine (CIRM), a program created in 2004 to boost stem cell research.

A vote against it would save money, but it might kill CIRM. The 16-year-old program ran out of its initial funding last year and it hasnt taken on new research since last summer, according to the state.

Stem cells, if youre wondering, are used in medical research on everything from nerve disorders and blindness to tooth decay.

Read our recommendation on how to votehere.

A yes vote would essentially create two distinct tracks (split roll) for state property taxes one for most commercial buildings and another for residential dwellings.

Under Prop. 15, the tax rate on most commercial and industrial properties would be based on the buildings market value, not its original purchase price. Exceptions would be made for buildings used in agriculture and for buildings owned by individuals or companies with less than $3 million in other assets. Overall, the state estimates it would generate up to $12.5 billion a year in new taxes from the owners of commercial properties.

A no vote would leave Californias Prop. 13 tax rules intact. All residential structures in California would continue to be taxed as they are now, with annual tax hikes jumping no more than the rate of inflation or 2%, whichever is lower.

Read our recommendation on how to votehere.

A yes vote on Prop. 16 would make it legal to consider race and gender, among other things, as potentially favorable factors when it comes to making decisions about public employment, public education and public contracting.

Technically, Prop. 16 is a constitutional amendment to repeal Prop. 209, a 1996 constitutional amendment approved by voters that ended the use of affirmative action in California.

Thus, a no vote would uphold Prop. 209.

Read our recommendation on how to votehere.

A yes vote for Prop. 17 would make it legal for people to vote while on parole for a felony conviction. Right now, in California, felons cant vote until after theyve served both their prison sentence and any parole. So were clear, Prop. 17 does not propose letting felons vote while in prison.

Read our recommendation on how to votehere.

A yes vote would allow 17-year-olds to vote in any primary or special election if they will turn 18 by the following general election

Read our recommendation on how to votehere.

This complicatedgrab bag of a proposal would allow older homeowners (those 55 and older), as well as disabled people and anyone who lost properties in a natural disaster, to take some of their property tax base with them when they sell a home and buy a new one.

It also would make it harder to keep a low property tax rate while transferring properties between generations.

And, finally, some of the new money generated by these changes would be used to help pay for firefighting.

Read our recommendation on how to votehere.

A yes vote for Prop. 20 would add to the states list of wobbler crimes, violations that currently are misdemeanors but, under this proposal, could be charged as felonies in some circumstances. Such crimes include organized petty theft, credit card scams and stealing a firearm, among others.

Prop. 20 also would create stiffer penalties for people who violate terms of their parole three times and make it tougher for those convicted of certain crimes including domestic violence to be considered for early parole. Finally, Prop. 20 would require that DNA samples be taken from people convicted of some misdemeanors.

Read our recommendation on how to votehere.

A yes vote on Prop. 21 would let cities write new rent control laws for older housing (15 years and older) or expand any rent control rules they already have on the books.

The proposal carves out an exception for single-family homes owned by landlords with no more than two properties. And, while Prop. 21 would wipe out the Costa-Hawkins Rental Housing Act (Costa-Hawkins) of 1995, it would not change the 7% rent hike limit set by state lawmakers last year.

Read our recommendation on how to votehere.

A yes vote on Prop. 22 would make an employee of gig-based companies such as Lyft or Uber an independent contractor same as before the passage of AB 5, which took effect in September 2019.

Under Prop. 22, rideshare and delivery companies that depend on such workers would not have to pay standard wage and hour restrictions, though they would have to provide an earnings floor and some money to purchase health insurance and mileage, among other things.

A no vote on Prop. 22 means existing law including AB 5 will apply to gig workers.

Its important to note that Prop. 22 is about people who use their own cars and cell phones as keys to their trade.

Read our recommendation on how to vote here.

A yes vote on Prop. 23 would mean at least one physician would have to be on site at an operating dialysis clinic. It also would require clinics to report on infections and get health department approval to close. And it would prohibit clinics from discriminating against patients based on how they pay for the clinics services.

Read our recommendation on how to votehere.

A yes vote on Prop. 24 would expand and add to Californias 2-year-old law on consumer data privacy and its reuse. Consumers could prohibit companies from sharing their personal information for any reason and shorten the period companies currently are given to fix the problem.

Prop. 24 also would create a Privacy Protection Agency to enforce the new rules.

Read our recommendation on how to votehere.

A no vote on Prop. 25 would maintain the cash bail system, letting people stay or leave jail while awaiting trial based largely on their ability to pay.

Read our recommendation on how to votehere.

Southern California News Group writer Andre Mouchard contributed to this story.

Read the rest here:
California propositions: What you should know before voting - The Mercury News

Cell Culture Market Research Report by Product, by Application – Global Forecast to 2025 – Cumulative Impact of COVID-19 – Yahoo Finance UK

Cell Culture Market Research Report by Product (Consumables and Equipment), by Application (Biopharmaceutical Production, Cell Banking, Diagnostics, Drug Screening & Development, and Stem Cell Research) - Global Forecast to 2025 - Cumulative Impact of COVID-19

New York, Oct. 08, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Cell Culture Market Research Report by Product, by Application - Global Forecast to 2025 - Cumulative Impact of COVID-19" - https://www.reportlinker.com/p05940079/?utm_source=GNW

The Global Cell Culture Market is expected to grow from USD 16,371.34 Million in 2019 to USD 33,826.78 Million by the end of 2025 at a Compound Annual Growth Rate (CAGR) of 12.85%.

Market Segmentation & Coverage: This research report categorizes the Cell Culture to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Product, the Cell Culture Market studied across Consumables and Equipment. The Consumables further studied across Bioreactor Accessories, Sera, Media, and Reagents, and Vessels. The Equipment further studied across Bioreactors, Storage Equipment, and Supporting Equipment.

Based on Application , the Cell Culture Market studied across Biopharmaceutical Production, Cell Banking, Diagnostics, Drug Screening & Development, Stem Cell Research, and Tissue Engineering & Regenerative Medicine.

Based on Geography, the Cell Culture Market studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas region surveyed across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific region surveyed across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa region surveyed across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Company Usability Profiles: The report deeply explores the recent significant developments by the leading vendors and innovation profiles in the Global Cell Culture Market including CellGenix GmbH, Corning Incorporated, Danaher Corporation, Eppendorf AG, Fujifilm Irvine Scientific, GE Healthcare, Hi-Media Laboratories, Invivogen, Lonza Group AG, Merck KGaA, Miltenyi Biotec, Promocell, Sartorius AG, and Thermo Fisher Scientific Inc..

FPNV Positioning Matrix: The FPNV Positioning Matrix evaluates and categorizes the vendors in the Cell Culture Market on the basis of Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Competitive Strategic Window: The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies. The Competitive Strategic Window helps the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. During a forecast period, it defines the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth.

Cumulative Impact of COVID-19: COVID-19 is an incomparable global public health emergency that has affected almost every industry, so for and, the long-term effects projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlaying COVID-19 issues and potential paths forward. The report is delivering insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecast, considering the COVID-19 impact on the market.

The report provides insights on the following pointers: 1. Market Penetration: Provides comprehensive information on the market offered by the key players 2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes the markets 3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments 4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, and manufacturing capabilities of the leading players 5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and new product developments

The report answers questions such as: 1. What is the market size and forecast of the Global Cell Culture Market? 2. What are the inhibiting factors and impact of COVID-19 shaping the Global Cell Culture Market during the forecast period? 3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Cell Culture Market? 4. What is the competitive strategic window for opportunities in the Global Cell Culture Market? 5. What are the technology trends and regulatory frameworks in the Global Cell Culture Market? 6. What are the modes and strategic moves considered suitable for entering the Global Cell Culture Market? Read the full report: https://www.reportlinker.com/p05940079/?utm_source=GNW

About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Here is the original post:
Cell Culture Market Research Report by Product, by Application - Global Forecast to 2025 - Cumulative Impact of COVID-19 - Yahoo Finance UK

U of T’s Medicine by Design invests $1 million to advance new ideas in regenerative medicine – News@UofT

Patients with cystic fibrosis experience recurrent lung infections that eventually destroy their airways, shortening their average life expectancy to 50 years in Canada. Current drug treatments, which target a malfunctioning pathway in cells that causes the infections, are costly and have varying effectiveness.

Now, with funding from Medicine by Design, a researcher at the Hospital for Sick Children (SickKids) is combining stem cells, gene editing and computational modelling to try to hijack an alternative cell pathway in the hopes of restoring lung function in these patients.

If successful, our study will be the first to provide proof-of-concept that this alternative approach to treating cystic fibrosis is effective, saysAmy Wong, a scientist working in developmental and stem cell biology at SickKids who is also an assistant professor in the department of laboratory medicine and pathobiology in the University of Torontos Temerty Faculty of Medicine.

Wongs project is one of seven across U of T and its affiliated hospitals that have been awarded 2020New Ideas AwardsandSeed Fundawards from Medicine by Design. Through a $1 million investment, Medicine by Design is supporting research aimed at advancing new concepts expected to be important to regenerative medicine in the coming years. The funded projects will have potential impacts in diseases and conditions such as vision loss, amyotrophic lateral sclerosis (ALS), intestinal disease in premature babies and more.

Supporting novel strategies and approaches is crucial to moving regenerative medicine into the future, saysMichael Sefton, executive director of Medicine by Designand a University Professor at U of Ts Institute of Biomedical Engineeringand thedepartment of chemical engineering & applied chemistry in the Faculty of Applied Science & Engineering.

Our 2020 New Ideas project portfolio integrates mathematical modelling, physics and computational biology with stem cell biology and biomedical engineering, and strengthens engagement with clinicians who are key to translating our research into patient impact. We are particularly delighted this year to support so many outstanding early-career researchers, who will ensure Toronto remains a global leader in regenerative medicine for years to come.

Wong is one of three investigators to receive a 2020 New Ideas Award, which is valued at $100,000 per year for up to two years. Four additional projects were selected for Seed Fund Awards of $100,000 each for one year to further develop their potential.

Medicine by Design selected the funded projects from among 36 short-listed proposals, which were evaluated and ranked through an external peer review process. Applications were submitted by clinicians and researchers at U of T and its affiliated hospitals from a wide range of disciplines including biochemistry, biomedical engineering, developmental and stem cell biology, immunology, neuroscience and surgery.

Medicine by Design builds on decades of made-in-Canada excellence in regenerative medicine dating back to the discovery of stem cells in the early 1960s by Toronto researchers James Till and Ernest McCulloch. Regenerative medicine uses stem cells to replace diseased tissues and organs, creating therapies in which cells are the biological product. It can also mean triggering stem cells that are already present in the human body to repair damaged tissues or to modulate immune responses. Increasingly, regenerative medicine researchers are using a stem cell lens to identify critical interactions or defects that prepare the ground for disease, paving the way for new approaches to preventing disease before it starts. Medicine by Design is made possible thanks in part to a $114-million grant from theCanada First Research Excellence Fund.

Current cystic fibrosis drug treatments target a genetic mutation that causes epithelial cells, which line the airway and act as a barrier against viruses, to function improperly. The mutation affects the function of an important ion channel in cells, called CFTR, which helps to maintain the right balance of fluid in the airways. Poor function causes mucosal obstructions in the airways and prevents clearance of foreign pathogens, which leads to chronic infections and ultimately destroys airway tissue.

In her project, Wong will explore an alternative ion channel in the epithelial cells to determine if it can be hijacked and used to compensate for the lack of function caused by the mutant CFTR. The research will be conducted using a combination of stem cell-derived lung models, gene editing and computational modelling.

Wongs project builds on decades of cystic fibrosis research at SickKids, where the cystic fibrosis gene was first identified 30 years ago.

To date, more than 2,000 mutations in the cystic fibrosis gene have been identified, says Wong. SickKids scientists and U of T researchers have become the epicentre of incredible cystic fibrosis research to understand how this disease works at the genetic and molecular level.

Wong says that, while the idea of targeting an alternative pathway is not necessarily ground-breaking on its own, its the array of tools now available that makes the idea a potential game changer.

We have access to an incredible resource of primary cells and stem cells from more than 100 individuals with cystic fibrosis harbouring various mutations. Wong says.Our lab has developed human lung models from stem cells that can be used to model lung disease such as cystic fibrosis. And with new advanced tools in single-cell genomics and gene-editing, coupled with key collaborations for computational modelling, we are poised to find new therapeutic targets for cystic fibrosis.

Leo Chou, an assistant professor at the Institute of Biomedical Engineering, andHyun Kate Lee, an assistant professor in the department of biochemistry in the Temerty Faculty of Medicineboth Medicine by Design New Investigators are also leading 2020 New Ideas projects.

Chou, along with co-investigatorsJulie Lefebvre, a scientist at SickKids and U of T assistant professor of molecular genetics, andValerie Wallace, a senior scientist at the Krembil Research Institute, University Health Network and a U of T professor of laboratory medicine and pathobiology and ophthalmology, will focus on cell transplantation in the retina, a process that has demonstrated encouraging pre-clinical results such as partial vision restoration in several animal disease models.

Recent research had demonstrated that this restoration is a result of the transfer of proteins complex molecules required for the structure, function and regulation of the bodys tissues between host tissue and donor cells. But the scope of that transfer process is not well understood. Chous project will develop an imaging approach to detect the transfer of mRNA molecules between host and donor cells. The outcomes from this project will inform the future design of cell transplantation therapies and lead to novel methods to deliver therapeutics. This project could improve therapies for retinal diseases and visual impairments, and inform strategies for other degenerative disorders.

Lee and co-investigatorPenney Gilbert,an associate professor at the Institute of Biomedical Engineering, will look at a common but not well-understood structure called the neuromuscular junction (NMJ), which mediates communication between neurons and muscles throughout the body. Defects in NMJ integrity and function underlie fatal diseases such as ALS. NMJ diseases, which affect more than 500,000 people globally, lack effective treatments. This project will use stem cells derived from reprogrammed skin cells of healthy people to develop NMJs in culture. Through high-resolution imaging, the healthy human NMJs will be studied both on their own and along with NMJs built from ALS patient cells. Through this work, the research team aims to identify genes to target to improve the health of NMJs, which could eventually help prevent or delay NMJ degeneration and even promote regeneration.

Michael Garton, an assistant professor at the Institute of Biomedical Engineering, has received a Seed Fund award to tackle the challenge of translating the genetic tools of synthetic biology an area of research that aims to create or redesign biological components using engineering methods into effective medical therapies against a number of diseases.

But they are difficult to translate into human therapies, Garton says, because the bodys T-cells immune cells that detect and destroy cells containing foreign material will identify these tools as foreign and destroy them.

Instead of switching off the T-cells, Gartons goal is to use computational modelling and high-throughput screening to selectively turn off the bodys foreign antigen display system so the immune system will still respond to foreign invaders when necessary, but allow cells containing synthetic tools to survive. If successful, this approach could enable a new generation of synthetic biology-enhanced cell therapies for a range of diseases.

Medicine by Design funding will help to facilitate the integration of synthetic biology and regenerative medicine and aid the development of cell-based therapies that perform better than nature, says Garton.

Other Seed Fund projects will encompass research in repairing the heart after paediatric cardiac surgery, treating an intestinal emergency in premature babies and creating a database for cell lineage paths.

John Parkinson, a senior scientist at SickKids and a U of T professor of biochemistry and molecular genetics, along with co-investigatorsJason Maynes, Wasser Chair in Anesthesia and Pain Medicine at SickKids and a U of Tassociate professor of anesthesiology and biochemistry, andWilliam Navarre, an associate professor in the department of molecular genetics, will investigate manipulating the microbiome, or community of microorganisms in the gut, to improve cardiac repair in post-operative treatment of a congenital heart disorder. Through a process that will identify prebiotics in breast milk that help enhance the production of molecules that research has shown can aid cardiac repair, the team will organize both observational (how disease alters the microbiome) and interventional (how the microbiome alters the disease) multi-site trials, which will provide the opportunity to immediately translate findings into changes in patient care regimens and improve outcomes.

CliniciansAgostino Pierro, a surgeon at the Division of General and Thoracic Surgery at SickKids and a U of T professor of surgery and physiology, and Philip Sherman, a senior scientist and gastroenterologist at the Division of Gastroenterology, Hepatology and Nutrition at SickKids and U of T professor of dentistry, pediatrics and laboratory medicine and pathobiology, have proposed a novel way of enhancing gut repair for a common intestinal emergency in premature babies, called necrotizing enterocolitis (NEC). A leading cause of death for these infants, NEC causes complications such as blindness, intellectual disability, repeat hospitalizations and gut damage even in those that survive. This project will look at whether intestinal organoids organ-like structures grown in the laboratory from stem cells that mimic some of the functions of native intestines can potentially stimulate repair of the gut and recovery from NEC. The project will define how to best transplant organoids, identify how the organoids protect the intestine from injury and assess if organoid transplantation is a valid new treatment for NEC.

Lincoln Stein, who is head of adaptive oncology at the Ontario Institute for Cancer Research and a professor in the department of molecular genetics at U of T, has received seed funding to build a database called Cytomics Reactome, which will be freely available to Canadian and international researchers. The database will build on recent technologies that open the door to the possibility of deciphering cell lineage paths the series of steps that lead a young, undifferentiated cell into a specialized one at single-cell resolution. To accelerate the path from basic research to clinical application, the database will systematically organize pre-existing knowledge of cell lineage paths into a comprehensive, interactive and easily accessible map that can serve as a framework for interpretation and integration of the latest experimental findings.

See original here:
U of T's Medicine by Design invests $1 million to advance new ideas in regenerative medicine - News@UofT